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views in our study. Our pooled anal-
ysis failed to show the efficacy of 
consolidation chemotherapy (CCT) 
in terms of survival prolongation for 
patients with locally advanced non–
small-cell cancer (LA-NSCLC). This 
negative result should carefully be 
assessed because, as Dr. Jermic sug-
gested, our study has several limita-
tions which might affect our study 
result.1 In particular, as our study was 
performed on a publication basis, we 
could not assess the heterogeneity 
at the individual patient level. It is 
important to identify the characteris-
tics of patients who could benefit from 
CCT. However, we could not carry out 
subgroup analyses based on the pat-
terns of treatment failure or responses 
to initial chemo-radiotherapies as our 
analysis did not use individual data of 
each trial.
Another important factor that 
may affect our study result is the 
diversity of CCT regimens among 
trials. We evaluated the effective-
ness of CCT by dividing it into two 
patterns: continuous CCT, which 
continues chemotherapy with agents 
given in the induction therapy, and 
switch CCT (SCCT), which switches 
chemotherapy to different agent(s) in 
the consolidation phase. SCCT might 
be more promising than continuous 
CCT because it is expected to effec-
tively eradicate tumor cells resistant 
to the induction chemo-radiotherapy. 
Although our analyses failed to show 
the efficacy of SCCT, it was prob-
ably because of the small number of 
trials: only four trials were designed 
for SCCT. Further clinical trials on 
SCCT will be warranted to answer 
these queries.
Finally, our pooled analysis 
failed to provide evidence that CCT 
yields significant survival benefit for 
LA-NSCLC patients. However, we 
believe that the findings of this study 
are relevant because it reminds us that 
there is currently no sufficient evi-
dence to support CCT for LA-NSCLC 
patients, and that current recommended 
treatment for LA-NSCLC patients 
remains concurrent chemo-radiother-
apy. Little progress in treatment strate-
gies for LA-NSCLC patients has been 
observed in the last 20 years,2 and it is 
urgent to seek new treatment options/
strategies to improve this. Further stud-
ies, for example, individual patient-
based meta-analyses or prospective 
studies focusing on patterns of treat-
ment failure or responses to initial 
chemo-radiotherapy are needed to 
establish how to use CCT appropriately 
to improve survival of LA-NSCLC 
patients.
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To the Editor:
We congratulate Huang et al.1 for 
their elegant description on how lung 
adenocarcinoma cells may metastasize to 
the ipsilateral parietal pleura, invade the 
chest wall lymphatic vessels which drain 
to the ipsilateral axillary lymph nodes, 
retrogradely spread to the intramammary 
lymphatics, and finally establish ipsi-
lateral breast metastasis. It is plausible 
that the presence of the clinical triad of 
ipsilateral pleural effusion or thickness, 
enlarged ipsilateral axillary lymph nodes 
that are palpable or evident on computed 
tomography (CT), and ipsilateral breast 
metastasis provides support for this pro-
posed mechanism for ipsilateral breast 
metastasis from lung cancer. In addition, 
the presence of intact fat planes between 
the chest wall and breast tissue on CT 
scan excludes direct tumor invasion of the 
breast from the ipsilateral parietal pleural 
metastasis as a less likely mechanism.1
We also like to add that the 
absence of enlarged mediastinal (N2 
or N3 disease) and ipsilateral supracla-
vicular (N3 disease) lymph nodes on 
CT scan and the latter also on palpa-
tion is needed to discount the other pos-
sible mechanism of lymphatic spread 
to ipsilateral axillary lymph nodes 
from mediastinal lymph nodes, through 
intercostal lymphatics2 or retrogradely 
through supraclavicular nodes.3
Whatever the mechanism of 
spread to the axillary lymph nodes, breast 
metastasis is an infrequent manifestation 
of advanced disseminated lung cancer 
and is associated with an extremely poor 
prognosis and a short survival.4,5
As Huang et al.1 has stated, differ-
entiating primary from metastatic breast 
carcinoma is of great clinical importance 
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because of the different clinical implica-
tion and management options. Metastatic 
breast lesions, which are very rare com-
pared with primary breast carcinoma, 
tend to be found in the subcutaneous fat, 
whereas primary breast cancers develop 
in the glandular tissue. As opposed to pri-
mary breast cancers, metastatic tumors 
to the breast are characteristically super-
ficially located, poorly defined, irregular 
nodules or masses without calcifica-
tion on mammography and ultrasound 
examination.5 
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